1832 Asset Management’s Blueprint Medicines BPMC Stock Holding History

1832 Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-502,651	Closed	-$54.2M	–	705
2024 Q2	$54.2M	Buy	502,651 +502,400	+200,159%	+$50.3M	0.04%	188
2024 Q1	$23.8K	Hold	251	–	–	﹤0.01%	720
2023 Q4	$23.2K	Hold	251	–	–	﹤0.01%	715
2023 Q3	$12.6K	Hold	251	–	–	﹤0.01%	743
2023 Q2	$15.9K	Hold	251	–	–	﹤0.01%	739
2023 Q1	$11.3K	Hold	251	–	–	﹤0.01%	788
2022 Q4	$11K	Hold	251	–	–	﹤0.01%	814
2022 Q3	$17K	Hold	251	–	–	﹤0.01%	775
2022 Q2	$13K	Hold	251	–	–	﹤0.01%	798
2022 Q1	$16K	Buy	+251	New	+$18K	﹤0.01%	848
2019 Q3	–	Sell	-24,100	Closed	-$2.24M	–	673
2019 Q2	$2.24M	Buy	+24,100	New	+$1.99M	0.01%	407
2018 Q2	–	Sell	-16,500	Closed	-$1.52M	–	665
2018 Q1	$1.52M	Buy	+16,500	New	+$1.42M	0.01%	407

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

1832 Asset Management's BPMC Position: Q3 2024 in Review

1832 Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 502,651 shares — an estimated $54.2M sold.

1832 Asset Management first reported a position in BPMC in Q1 2018 and held it in 12 quarters. The position peaked at $54.2M in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

1832 Asset Management reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
1832 Asset Management sold 502,651 Blueprint Medicines shares in Q3 2024, an estimated $54.2M.
1832 Asset Management first reported a position in Blueprint Medicines in Q1 2018 and held it in 12 quarters.
1832 Asset Management's Blueprint Medicines position peaked at $54.2M in Q2 2024.
319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.